Phase II study of topotecan and bevacizumab in advanced, refractory non-small-cell lung cancer

Keyphrases

• Non-small Cell Lung Cancer (NSCLC) 100%
• Phase II Study 100%
• Bevacizumab 100%
• Topotecan 100%
• Progression-free Survival 40%
• Interferon-stimulated Gene 15 (ISG15) 40%
• Gene Expression 20%
• Clinical Trials 20%
• Intravenous Infusion 20%
• 18 Years Old 20%
• Prior Treatment 20%
• Anemia 20%
• Pulmonary Embolism 20%
• Thrombocytopenia 20%
• Progressive Disease 20%
• Treatment Regimen 20%
• Stable Disease 20%
• Neutropenia 20%
• Metastatic Non-small Cell Lung Cancer 20%
• Overall Survival 20%
• Response Rate 20%
• Adverse Events 20%
• Salvage Therapy 20%
• Hematotoxicity 20%
• Tumor Specimens 20%
• Partial Response 20%
• Pulmonary Hemorrhage 20%
• Median Progression-free Survival 20%
• Biomarkers of Response 20%
• Bevacizumab Therapy 20%
• Days of Treatment 20%
• Treatment Cycle 20%
• Nonhematologic 20%
• Toxic Death 20%

Medicine and Dentistry

• Topotecan 100%
• Non Small Cell Lung Cancer 100%
• Bevacizumab 100%
• Progression Free Survival 60%
• Disease 20%
• Biological Marker 20%
• Clinical Trial 20%
• Neoplasm 20%
• Intravenous Drug Administration 20%
• Gene Expression 20%
• Adverse Event 20%
• Pulmonary Embolism 20%
• Anemia 20%
• Neutropenia 20%
• Progressive Disease 20%
• Salvage Therapy 20%
• Overall Survival 20%
• Pulmonary Hemorrhage 20%
• Thrombocytopenia 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Non Small Cell Lung Cancer 100%
• Bevacizumab 100%
• Topotecan 100%
• Progression Free Survival 60%
• Disease 40%
• Clinical Trial 20%
• Biological Marker 20%
• Adverse Event 20%
• Lung Embolism 20%
• Overall Survival 20%
• Lung Hemorrhage 20%
• Anemia 20%
• Neoplasm 20%
• Thrombocytopenia 20%
• Neutropenia 20%